Cardioprotective effects of peroxisome proliferator activated receptor γ activators on acute myocarditis: Anti-inflammatory actions associated with nuclear factor κB blockade

Heart

Volumn 91, Issue 9, 2005, Pages 1203-1208

  Yuan, Zuyi ^a   Liu, Y ^a,a   Zhang, J ^a   Kishimoto, C ^b   Wang, Y ^a   Ma, A ^a   Liu, Z ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; GEL MOBILITY SHIFT ASSAY; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; AUTOIMMUNE DISEASES; CARDIOTONIC AGENTS; CYTOKINES; GENE EXPRESSION REGULATION; MYOCARDITIS; MYOSINS; NF-KAPPA B; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, INBRED LEW; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 23944521775     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.046292     Document Type: Article

References (33)

1. Matsumori A, Yamada T, Suzuki H, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-6.
2. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
3. Henriksen PA, Newby DE. Therapeutic inhibition of tumour necrosis factor with heart failure: cooling the inflamed heart. Heart 2003;89:14-8.
4. Yuan Z, Shioji K, Kihara Y, et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004;286:83-90.
5. Sidhu JS, Kaski JC. Peroxisome proliferator activated receptor γ: a potential therapeutic target in the management of ischaemic heart disease. Heart 2001;86:255-8.
6. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-71.
7. Marx N, Schonbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-103.
8. Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
9. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
10. Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004;483:79-93.
11. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998;95:7614-9.
12. Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
13. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
14. Daib A, Deng C, Smith JD, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002;168:2508-15.
15. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002;51:694-702.
16. Yuan Z, Liu Y, Liu Y, et al. Peroxisome proliferator-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis associated with inhibition of self-sensitive T cells. J Cardiovasc Pharmacol 2004;43:868-75.
17. Kodama M, Matsumoto Y, Fujiwara M, et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62.
18. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 2001;89:540-6.
19. Yue T, Bao W, Jucker BM, et al. Activation of peroxisome proliferator-activated receptor-α protects the heart from iscnemia/reperfusion injury. Circulation 2003;108:2393-9.
20. Matsui Y, Inobe M, Okamoto H, et al. Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis. J Mol Cell Cardiol 2002;34:279-95.
21. Lane JR, Neumann DA, Lafond-Walker A, et al. Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 1992;175:1123-9.
22. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-81.
23. Chung MK, Gulick TS, Rotondo RE, et al. Mechanism of cytokine inhibition of β-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes: impairment of signal transduction. Circ Res 1990;67:753-63.
24. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;57:387-9.
25. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703-10.
26. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor κB (NF-κB): an emerging theme in anti-inflammatory therapies. Mol Intervent 2002;2:22-35.
27. Delerive P, Gervois P, Fruchart JC, et al. Induction of I κBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem 2000;275:36703-7.
28. Vanden-Berghe W, Vermeulen L, Delerive P, et al. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 2003;544:181-96.
29. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002;16:1027-40.
30. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;106:3126-32.
31. Purcell NH, Tang G, Yu C, et al. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 2001;98:6668-73.
32. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000;403:103-8.
33. Yokoseki O, Suzuki J, Kitabayashi H, et al. cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906.